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Abstract
The P2Y6 receptor is a cytoprotective G protein-coupled receptor (GPCR) activated by UDP
(EC50, 0.30 μM). We compared and combined modifications to enhance P2Y6 receptor agonist
selectivity, including ribose ring constraint, 5-iodo and 4-alkyloxyimino modifications, and
phosphate modifications such as α,β-methylene and extension of the terminal phosphate group into
γ-esters of UTP analogues. The conformationally constrained (S)-methanocarba UDP is a full agonist
(EC50 0.042 μM). 4-Methoxyimino modification of pyrimidine enhanced P2Y6, preserved P2Y2 and
P2Y4, and abolished P2Y14 receptor potency, in the appropriate nucleotide. N4-Benzyloxy-CDP
(15, MRS2964) and N4-methoxy-Cp3U (23, MRS2957) were potent, selective P2Y6 receptor agonists
(EC50 0.026 μM and 0.012 μM, respectively). A hydrophobic binding region near the nucleobase
was explored with receptor modeling and docking. UTP-γ-aryl and cycloalkyl phosphoesters
displayed only intermediate P2Y6 receptor potency, but had enhanced stability in acid and cell
membranes. UTP-glucose was inactive, but its (S)-methanocarba analogue and N4-methoxy-cytidine
5′-triphospho-γ-[1]glucose were active (EC50 of 2.47 μM and 0.18 μM, respectively). Thus, the
potency, selectivity, and stability of pyrimidine nucleotides as P2Y6 receptor agonists may be
enhanced by modest structural changes.
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The P2Y receptors are G protein-coupled receptors (GPCRs) that respond to naturally-
occurring extracellular nucleotides including ATP, ADP, UTP, UDP, and UDP-glucose.1 Five
of the eight subtypes, P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 receptors, are preferentially coupled
through Gq to activate phospholipase Cβ (PLC-β) and represent a distinct structural subfamily.
2 The remaining P2Y12, P2Y13, and P2Y14 receptors are coupled to inhibition of adenylate
cyclase. Activation of the P2Y6 receptor by its native ligand UDP 1 (Chart 1) is associated
with vasoconstriction and cytoprotection.3-6 We reported the effects of P2Y6 receptor agonists
to counteract apoptosis induced by tumor necrosis factor-α in astrocytoma cells stably
expressing the human P2Y6 receptor and in mouse C2C12 skeletal muscle cells and MIN6
pancreatic cells that express an endogenous P2Y6 receptor.4-6 Furthermore, in vivo
administration of 5-iodo-UDP (MRS2693) 3, which is a selective P2Y6 receptor agonist,
induced protection in a model of ischemia in hindleg skeletal muscle.6 The dinucleoside
triphosphate INS48823 4 activates the P2Y6 receptor in bone and increased survival of
osteoclasts.7 A role for the P2Y6 receptor in inducing phagocytosis in microglial cells was
recently discovered, suggesting the possible application of P2Y6 receptor ligands for the
treatment of neurodegenerative conditions.8 The P2Y6 receptor is upregulated when neurons
are damaged and in intestinal inflammation.8,9 UDP applied topically to the cornea reduced
intraocular pressure, suggesting the use of P2Y6 receptor agonists for the treatment of ocular
hypertension and glaucoma.10 Studies of mice lacking the P2Y6 receptor recently demonstrated
a defective response to UDP in macrophages, endothelial cells, and vascular smooth muscle
cells.11 Thus, pharmacological modulation of the P2Y6 receptor is of increasing interest for
future therapeutics.12
Potent P2Y6 receptor agonists, such as 3-phenacyl-UDP 5 with an EC50 value of 70 nM, have
been reported.13-16 Recently, we reported that UDP also activates the P2Y14 receptor, and
therefore, agonists that delineate between these two subtypes are needed.17,18 We have adopted
a structure-based approach to developing P2Y6 receptor agonist ligands with improved
potency, selectivity, and stability. In the absence of an X-ray structure, rhodopsin-based
homology modeling has predicted a putative binding site for nucleotides in the human P2Y6
receptor.13 The receptor recognition of the 5′-diphosphate group is associated with three
cationic residues in the transmembrane region, which serve as counterions and which are
conserved in charge across the five Gq-coupled P2Y receptors.2 A Monte Carlo analysis of
conformations of receptor-docked UDP molecules, followed by molecular dynamics of the
receptor-ligand complex in a lipid bilayer model, has predicted that the South (S) conformation
of the ribose ring is preferred at the P2Y6 receptor.13 This is the only Gq-coupled P2Y subtype
at which the (S) conformation of the ribose or a ribose-like moiety of nucleotide ligands appears
to be favored, and our comparison of the weak agonist 2′-deoxy-UDP 2 and the corresponding
2′-deoxy (S)-methanocarba analogue 613,14 supported this idea.
We recently reported the first synthetic route to the enantiomerically pure (S)-methanocarba-
uridine,19 and in this study we examined the hypothesis that the (S) conformation is preferred
at the P2Y6 receptor in the more potent 2′-hydroxynucleotide series. Modifications of the
pyrimidine ring of UDP, including 5-iodo and 4-alkyloxyimino, and of the phosphate moiety,
including α,β-methylene, and extension of the terminal phosphate group, were compared and
combined in an effort to further enhance selectivity for the P2Y6 receptor.14,16 Chemical and
metabolic instability of mononucleotides is well-documented.20 Mononucleotides are
degraded enzymatically by ectonucleotidases into the lower nucleotides and eventually into
the nucleoside. Chemical degradation of nucleotides is also evident at pH ranges less than 4
or greater than 10. The degradation products of nucleotides may interact with multiple P2Y
receptors or with adenosine receptors and lead to side effects. Since various dinucleotides, such
as diuridine triphosphates, show greater stability than analogues of mononucleotides,21,22 we
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A series of known (1-6, 8, 10, and 11) and newly synthesized derivatives of UDP (7, 9) and
CDP (12-16) was assembled and compared (Tables 1 and 2). Novel analogues of UTP and
Up3U (18, 20, and 22-33) also were included in this structure activity relationship (SAR)
analysis (Table 3). The chemical synthesis of ribonucleoside 5′-di and triphosphate derivatives
(Scheme 1) was performed by standard phosphorylation methods using the unprotected
nucleoside precursors.23,24 Various 5′-diphosphate derivatives were then extended to form
dinucleoside triphosphates or other 5′-triphosphate γ-esters (Scheme 2). (S)-Methanocarba
nucleotides were synthesized as shown in Scheme 3. The synthesis of several of the pyrimidine
nucleotides was reported in previous studies of the P2Y receptor (3, 5, 6, 8, 10, 19, 21, and
26).14-16
5-Iodouridine 34 was available from commercial sources, while the 4-methoxyimino derivative
36 and (S)-methanocarba-uridine 41 were prepared as described,19,25 and compounds 37-39
were prepared by the same procedure as 36. Compounds 34 and 36 were converted to the
α,β-methylene diphosphonate analogues 11 and 16, respectively, by a carbodiimide
condensation. N4-Alkoxy-cytidines 36-39 were converted to the corresponding 5′-
diphosphates 12-15 and N4-methoxy-cytidine 36 to the 5′-triphosphate 20 using phosphorous
oxychloride followed by either phosphate or pyrophosphate.24 Various 5′-diphosphates (1, 3,
5, 10, and 12) were converted to the corresponding 5′-triphosphate γ-esters by condensation
with the appropriate monophosphate derivative in DMF.
Nucleotides 18 and 28 derived from (S)-methanocarba-uridine 40 were prepared by similar
phosphorylation of the unprotected nucleoside (Scheme 3).24 The 3′,5′-cyclic diphosphate 9
was isolated as a side product in the synthesis of 28. A similar cyclic diphosphate was isolated
following phosphorylation of other uridine analogues.14
Pharmacological evaluation
The nucleotide analogues (Tables 1 – 3) were assayed for capacity to promote activation of
phospholipase C (PLC) in 1321N1 human astrocytoma cells stably expressing the human
P2Y6 receptor.26 Receptor selectivity of the novel analogues of CDP and UTP in Tables 2 and
3 was assessed by quantification of PLC activation in 1321N1 cells stably expressing either
the P2Y2 receptor or the P2Y4 receptor. Previously reported data for several analogues (2 – 6,
8, and 10) were included for comparison.
The enantiomerically pure (S)-methanocarba-UDP 7 was more potent at the P2Y6 receptor
than either UDP 1 (7-fold) or the previously reported (S)-methanocarba-2′-deoxy-UDP 6 (5-
fold). In contrast, the North (N)-methanocarba conformationally locked UDP analogue 8 was
previously found to be inactive at the P2Y6 receptor, confirming a strong conformational
preferrence in P2Y6 receptor recognition.13,14 The (S)-methanocarba-uridine-3′,5′-cyclic
diphosphate 9 was also inactive at the P2Y6 receptor.
The carbon-bridged analogue α,β-methylene-UDP 10 was recently reported to be nearly as
potent as UDP at the P2Y6 receptor.16 Compound 11 contained the 5′-α,β-
methylenediphosphonate modification, which would increase the stability of a nucleotide in
biological systems, and the 5-iodo modification (as in 3), both of which were previously noted
to preserve potency at the P2Y6 receptor.14 This combination of modifications resulted in a
molecule 11 that potently activated the P2Y6 receptor with an EC50 value of 127 nM.
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Introduction of the 4-methoxyimino modification of UDP, i.e., N4-methoxy-CDP 12, resulted
in high potency at the P2Y6 receptor (EC50 70 nM), which represents a 4-fold gain of potency
over UDP (Table 2, Figure 1A). Compound 12 was 47-fold selective for activation of PLC via
the P2Y6 receptor in comparison to inhibition of cyclic AMP accumulation in HEK-293 cells
expressing the Gi-coupled human P2Y14 receptor.18 The native agonist for P2Y14, UDP-
glucose, did not tolerate the 4-methoxyimino substitution.27 However, the 4-methoxyimino
modification of the pyrimidine ring in the 5′-triphosphate derivative 20 produced a gain of
potency (EC50 80 nM) of >100-fold over UTP 17 at the P2Y6 receptor (Table 3). The 4-
methoxyimino modification of 20 was also well-tolerated at the P2Y2 and P2Y4 receptors, with
EC50 values of 50 nM. Thus, compound 20 was a nonselective agonist at these three P2Y
receptor subtypes.
In the series of 4-alkyloxyimino 5′-diphosphate analogues, the progression from MeO to larger
O-alkyl substituents 12 – 15, first decreased then increased the P2Y6 receptor potency. The
sterically bulky O-t-butyl group of 14 was not well tolerated. However, the O-benzyl analogue
15 was the most potent P2Y6 receptor agonist in the series of 4-imino 5′-diphosphate analogues
with 82- and 44-fold selectivity vs. P2Y2 and P2Y4 receptors, respectively. Curiously, the O-
ethyl analogue 13 was potent at P2Y2 and P2Y4 receptors and was thus a non-selective
hP2Y2/4/6 agonist. The potency-enhancing 4-methoxyimino modification was combined with
α,β-methylene substitutions in compound 16. However, there was no enhancement by the 4-
methoxyimino modification, as 10 and 16 were equipotent at the P2Y6 receptor.
Up3U 21 slightly favored activation of the P2Y6 receptor, in comparison to the P2Y2 and
P2Y4 receptors, with an EC50 value of 270 nM.16 Introduction of a carbon bridge in the
corresponding α,β-methylene analogue 22 reduced P2Y6 receptor potency 5-fold, but with
increased selectivity. Given the P2Y6 receptor potency of extended phosphate derivatives, such
as dinucleoside triphosphates related to Up3U 21 (including 4), we tested other γ-phosphoesters
of UTP for P2Y6 receptor activity, including alkyl and aryl esters and Up3-sugar derivatives.
The analogue of Up3U containing a single 4-methoxyimino modification 23 displayed 22-fold
enhanced potency at the P2Y6 receptor with an EC50 value of 12 nM and selectivity versus the
P2Y2 and P2Y4 receptors of 14- and 66-fold, respectively. The γ-cyclohexyl 25 and γ-phenyl
26 esters of UTP displayed moderate potency at the P2Y6 receptor, with EC50 values of 6.99
and 2.13 μM, respectively. However, Up3-[1]glucose 27 only weakly activated the P2Y6
receptor, and an EC50 value was not determined. The introduction of the potency enhancing
(S)-methanocarba modification in the corresponding ring-constrained analogue 28 increased
potency, as predicted. Nevertheless, only a moderate potency of 2.47 μM was attained.
Combinations of Up3-glucose with other known modifications that are tolerated or favored at
the P2Y6 receptor were evaluated. Introduction of the 5-iodo modification in 29 only slightly
enhanced potency in comparison to 27. The corresponding 3-phenacyl 30 and α,β-methylene
31 analogues were only weakly active at the P2Y6 receptor. However, the P2Y6 receptor
potency of the corresponding N4-methoxy-cytidine analogue 32 was greatly increased with an
EC50 value of 180 nM, which also displayed >100-fold selectivity versus P2Y2 and P2Y4
receptors. This finding suggested another analogue, N4-methoxy-cytidine-5′-triphosphate γ-
phenyl ester 33, but an additive effect on potency was absent, as it weakly activated the
P2Y6 receptor (EC50 3.49 nM).
Selected nucleotide analogues were also examined for the ability to raise levels of intracellular
calcium ions in 1321N1 human astrocytoma cells expressing the human P2Y6 receptor (Figure
1B). The rank order of potency was 23, 3 > 21, 24, which was similar to the order of potency
in PLC activation.
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Stability of Nucleotide Derivatives
The chemical and enzymatic instability of nucleotide analogues in biological systems is a major
limitation in their use as pharmacological probes. Therefore, to assess their potential for broad
use, selected nucleotide derivatives were evaluated for stability during prolonged exposure to
two different conditions. The derivatives were incubated at 37°C in aqueous medium at low
pH or in the presence of 1321N1 astrocytoma membranes, which are known to contain
ectonucleotidases, as a representative mammalian cell of the central nervous system. At regular
intervals aliquots were taken for HPLC analysis (Table 4 and Supporting Information). The
injection sample was pre-diluted with 5 mM tetrabutylammonium dihydrogenphosphate
(TBAP) to allow complete equilibration with the mobile phase, in order to avoid the early
HPLC elution at around one minute.
The stability in the presence of cell membranes was 25, 22 > 12 >21, 26 > 17, 27 > 15, 23 >
31. The potent P2Y6 receptor agonist 12 was more stable than the related N4-benzyloxy cytidine
5′-diphosphate 15. The γ-cyclohexyl ester 25 was more stable than either Up3U 21, which has
a uridyl group at this terminal position, or the γ-phenyl ester 26. The α,β-methylene analogue
of Up3U 22 was more stable than the parent Up3U 21 in the presence of cell membranes, which
may indicate that a α,β-methylene bridges blocks enzymatic breakdown, as has been observed
for other P2 receptor agonists containing phosphonates.16,28,29 However, the introduction of
a methylene bridge into Up3U unfortunately also reduced potency at the P2Y6 receptor 5-fold.
In acidic solution, the CDP derivatives 12 and 15 and the dinucleoside triphosphates were of
enhanced chemical stability. Also, the γ-phenyl phosphoester 26 was relatively stable.
However, the Up3U analogue 22 containing a α,β-methylene bridge was significantly less
stable than the parent Up3U 21. Likewise, the Up3-[1]glucose analogue 31 containing a α,β-
methylene bridge was less stable than the parent Up3-[1]glucose 27, which itself was very
labile. Since both of the glucose derivatives 27 and 31 were rapidly degraded, the introduction
of glucose was not a favored modification.
Molecular Modeling
A docking of the semi-rigid (S)-methanocarba analogue 7 in complex with our rhodopsin-based
P2Y6 receptor model13 (Figure 2A) suggested that 7 establishes with the receptor the same
putative interactions characteristic of UDP. In particular, three cationic residues located in
transmembrane domain 3 (TM3), TM6, and TM7 coordinate the diphosphate of 7, namely
R103(3.29), K259(6.55), and R287(7.39), while the base is coordinated by Y33(1.39) and S291
(7.43), located in TM1 and TM7, respectively – see Experimental Section for residue indexing.
The higher potency of 7 compared to UDP is induced by the rigid methanocarba scaffold, which
constrains the ribose in the bioactive conformation, likely with a consequent gain in the entropic
component of the binding affinity. A hydrogen bond is possibly formed between the ribose 2′-
hydroxy group and the uracil 2-oxo group of 7 (Figure 2A). Furthermore, as shown in Figure
2A, the molecular dynamics simulation predicted the access of several water molecules to the
receptor binding pocket from the extracellular milieu. These molecules surround the portion
of the ligand exposed to the extracellular opening of the binding site, including the 5 position
of the uracil ring. For entropic reasons, substituents capable of displacing these water molecules
from the binding cavity to the bulk of the solvent are expected to enhance the affinity of the
compounds. The increase in affinity noted upon the introduction of the iodo-substituent at the
5-position of the uracil ring (see compounds 1 and 3) is consistent with this reasoning and
supports the orientation of this moiety of the ligand towards the extracellular opening of the
helical bundle of the receptor as suggested by our models.
A molecular model of N4-methoxy-CDP 12 docked in the P2Y6 receptor showed similar
coordination to that of UDP, i.e., S291(7.43) coordinates the base, and four cationic residues
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coordinate the diphosphate moiety (Figure 2B). The methyl group at the 4 position seems to
fit well in a sterically restricted hydrophobic pocket, which consisted of V32(1.38), Y33(1.39),
I83(2.61) and P288(7.40). These hydrophobic interactions may be the reason for the increased
activity of 12 (Table 2).
Discussion
The present set of analogues provides new insights into the structural requirements for
activation of the P2Y6 receptor at each of the three regions modified: ribose, nucleobase, and
terminal phosphate. In addition to studying the SAR of pyrimidine nucleotides in receptor
activation, we have also confirmed that blockade of the terminal phosphate with an alkyl or
aryl group or other groups may increase its stability.
Using sterically constrained carbocyclics, we have extended to the ribo (2′-hydroxy) series the
prediction that the (S) conformation of a ribose-like moiety is preferred for recognition at the
human P2Y6 receptor, consistent with previous activity of the 2′-deoxy analogues. The first
synthesis of enantiomerically pure (S)-methanocarba-uridine enabled the preparation of
nucleotide derivatives in the 2′-hydroxy series (7, 18, and 28). These (S)-methanocarba
nucleotides exhibited enhanced potency over the corresponding natural ribose analogue in each
case.
In homology-based modeling of the P2Y6 receptor and ligand docking, an intramolecular
hydrogen bond was detected between the 2′-hydroxy group and the uracil 2-oxo group of the
conformationally constrained, potent analogue of UDP 7. We suggest that this interaction might
further restrain 7 in its bioactive conformation, and thus, contribute to the greater potency of
7 over the corresponding 2′-deoxy analogue 6.
One of the striking findings of this study was that the 4-methoxyimino and 4-benzyloxyimino
modifications of the pyrimidine ring in the appropriate nucleotide derivative served to enhance
potency at the P2Y6 receptor. This is one of the few modifications of the uracil ring that is
tolerated for activation of the P2Y6 receptor. CDP itself is nearly inactive at the human
P2Y6 receptor, and its EC50 at the P2Y14 receptor is >10 μM.17,30 The 4-methoxyimino 5′-
diphosphate analogue 12 displayed a selectivity of 51- and 47-fold versus the P2Y2 and
P2Y14 receptors, respectively, and a substituent as large as O-benzyl 15 was tolerated. In the
5′-triphosphate analogue 20, the 4-methoxyimino modification also preserved potency at
P2Y2 and P2Y4 receptors and abolished potency at the P2Y14 receptor.27 In Schemes 1 and 2,
the imino group of N4-methoxycytidine is depicted as the imino-oxo tautomer, based on an
early study of the poly C derivative after treatment with methoxyamine.31 This predominant
form, which resembles the major lactam (keto) tautomer of UDP, was used in the molecular
modeling. However, the amino tautomeric form, which is found in native cytosine in DNA,
might also be present. The 4-methoxyimino group in a γ-[1]glucose triphosphate ester 32 also
enhancedpotency. However, the γ-[1]glucose triphosphate in another analogue 27 suffered
from low stability, and therefore, 32 is not a likely candidate for generation of a potent and
stable agonist.
The introduction of a phenyl or cyclohexyl ring at the terminal phosphate of UTP in compounds
25 and 26, respectively, enhanced stability in both acidic solution and in the presence of
membranes to at least the same extent as Up3U. Both 25 and 26 containing terminal
hydrophobic groups showed higher potency than UTP 17 at the P2Y6 receptor, and the more
hydrophilic Up3-[1]glucose 27 was nearly inactive. Thus, the nature of the terminal group can
greatly affect agonist activity. Since Up4-[1]glucose is a potent agonist of the P2Y2 receptor,
and Up2-[1]glucose is a native agonist of the P2Y14 receptor, we speculated that the
intermediate triphosphate homologue 27 might be an effective agonist of the P2Y6 receptor.
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However, this receptor is not as tolerant of a terminal glucose moiety as are the P2Y2 and
P2Y14 receptors. Nevertheless, the introduction of a rigid (S)-methanocarba ring system in
18 and 28 resulted in agonists that exceeded the P2Y6 potency of both UTP and Up3-[1]glucose.
The combination of two modifications in the present set of compounds either produced an
additive effect on P2Y6 receptor potency, as in γ-[1]glucose triphosphate ester 32, or failed to
increase potency, as in the γ-phenyl ester 33 and the α,β-methylene analogue 16. The
inconsistent effects of combination of various structural modifications on receptor recognition
suggested multiple modes of binding of these nucleotide series.
The homology modeling and docking, interpreted in light of the biological activity, indicate
conformational cross-talk between the nucleobase and the terminal phosphate substituent.
Although the molecular model of N4-methoxy-CDP 12 docked in the P2Y6 receptor showed
similar coordination to that of UDP, Up3-O-phenyl 26 docked a different mode (not shown).
The base of 26 did not coordinate with Y33(1.39) and S291(7.43), because the position of the
base had shifted within the binding site. Also, the ribose ring showed a planar rather than a (S)
conformation. The terminal phenyl group of 26 seemed to fit in a hydrophobic region in the
model, which might be the reason for the dislocation of the nucleobase, i.e. by withdrawal of
the entire molecule. On the other hand, the docked model of N4-methoxy-Cp3-O-phenyl 33 in
the receptor showed a position and coordination similar to N4-methoxy-CDP 12, but the phenyl
ring did not interact with the distal hydrophobic region occupied by 26. The strong interaction
of the methyl group of 33 in a hydrophobic pocket near the nucleobase may cause the phenyl
group to exit its large hydrophobic binding region. This interpretation is consistent with the
lack of enhanced activity of compound 33 in comparison to Up3-O-phenyl 26, despite the
presence of methoxyimino moiety at the 4 position.
The modeling and receptor docking also predicted that various water molecules are located in
proximity of the 5 position of the ligand. The enhanced affinity of the 5-iodo-substituted
analogues could be a result of the fact that the halogen displaced some of the structured water
molecules present in the binding site, with a consequent entropic gain.
Conclusions
We have identified novel nucleotides, such as N4-alkoxy-cytidine derivatives, that are more
potent, selective, and potentially more stable in vivo than both the native agonist and previously
reported synthetic agonists of the P2Y6 receptor. Thus, N4-methoxy-cytidine nucleotides 12,
15, and 23 were relatively potent and selective agonists, and moreover, compound 23 displayed
favorable stability. Thus, in future SAR studies (S)-methanocarba-(α,β-CH2)N4-OMe-CDP
could be a suitable combination to maximize the potency, while retaining selectivity and
stability.
The P2Y6 receptor is implicated in neurodegeneration, osteoporosis, ischemic effects in
skeletal muscle, and possibly diabetes.4,32,33 Therefore, new potent and selective ligands are
of interest in the search for new treatments for these conditions. Agonists of the P2Y6 receptor
are predicted to produce beneficial responses in for example muscle wasting and possibly
neurodegeneration, and several compounds such as 23 from the present SAR analysis could
provide useful pharmacological tools.
Experimental Section
Synthesis
1H NMR spectra were obtained with a Varian Gemini 300 or Varian Mercury 400 spectrometer
using D2O, CDCl3 or DMSO-d6 as a solvent. The chemical shifts are expressed as relative
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ppm from HOD (4.80 ppm). 31P NMR spectra were recorded at room temperature (rt) by use
of Varian XL 300 (121.42 MHz) or Varian Mercury 400 (162.10 MHz) spectrometers;
orthophosphoric acid (85%) was used as an external standard. In several cases the signal of the
terminal phosphate moiety was not visible due to high dilution.
Purity of compounds was checked using a Hewlett–Packard 1100 HPLC equipped with a
Zorbax Eclipse 5 μm XDB-C18 analytical column (250 × 4.6 mm; Agilent Technologies Inc,
Palo Alto, CA). Mobile phase: linear gradient solvent system: 5 mM TBAP-CH3CN from 80:20
to 40:60 in 20 min; the flow rate was 1 mL/min (System A) or Zorbax SB-Aq 5 μm analytical
column (50 × 4.6 mm; Agilent Technologies Inc, Palo Alto, CA). Mobile phase: linear gradient
solvent system: 5 mM TBAP-CH3CN from 80:20 to 40:60 in 13 min; the flow rate was 0.5
mL/min (System B). Peaks were detected by UV absorption with a diode array detector at 254,
275, and 280 nm. All derivatives tested for biological activity showed >99% purity by HPLC
analysis (detection at 254 nm).
High-resolution mass measurements were performed on Micromass/Waters LCT Premier
Electrospray Time of Flight (TOF) mass spectrometer coupled with a Waters HPLC system,
unless noted. Purification of the nucleotide analogues for biological testing was carried out on
(diethylamino)ethyl (DEAE)-A25 Sephadex columns with a linear gradient (0.01–0.5 M) of
0.5 M ammonium bicarbonate as the mobile phase. Compounds 7 were purified by Sephadex
alone (and isolated in the ammonium salt form), and all other compounds were purified by
HPLC with a Luna 5 μ RP-C18(2) semipreparative column (250 × 10.0 mm; Phenomenex,
Torrance, CA) and using the following conditions: flow rate of 2 mL/min; 10 mM
triethylammonium acetate (TEAA)-CH3CN from 100:0 to 95:5 (or up to 100:0 to 75:25) in
20-40 min (and isolated in the triethylammonium salt form).
All reagents were of analytical grade. 3-Phenacyl-UDP 5 was purchased from Tocris. 5-
Iodouridine 34 was purchased from Berry Associates (Ann Arbor, MI). Compound 36 were
synthesized as reported.19,25 Other reagents and solvents were purchased from Sigma-Aldrich
(St. Louis, MO).
(S)-Methanocarba-uridine-5′-diphosphate triethylammonium salt (7)
A solution of the (S)-methanocarba-uridine 40 (1-[(1S,2S,5S,3R,4R)-2,3-dihydroxy-4-
(hydroxymethyl) bicyclo[3.1.0]hexyl]-1,3-dihydropyrimidine-2,4-dione, 10 mg, 0.04 mmol,
ref. 13) and Proton Sponge (17 mg, 0.08 mmol) in trimethyl phosphate (1 mL) was stirred for
10 min at 0 °C. Then phosphorous oxychloride (0.008 mL, 0.08 mmol) was added dropwise,
and the reaction mixture was stirred for 2 h at 0 °C. A mixture of tributylamine (0.8 mL, 0.35
mmol) and a solution 0.35 M of the bis(tributylammonium) salt of phosphoric acid in DMF
(0.7 mL) was added at once. After 10 min, 0.2 M triethylammonium bicarbonate solution (1.5
mL) was added, and the clear solution was stirred at rt for 1 h. After removal of solvents, the
residue was purified using the same method as the general procedure using Sephadex-DEAE
A-25 resin and HPLC to get compound 7 (1.3 mg, 45%) as a white solid. 1H NMR (D2O) δ
7.79 (d, J = 7.8 Hz, 1H), 5.86 (d, J = 8.1 Hz, 1H), 4.69 (m, 1H), 4.15 (m, 3H), 2.39 (t, J = 6.3
Hz, 1H), 1.87 (m, 1H), 1.71 (t, J = 6.0 Hz, 1H), 1.30 (ddd, J = 2.1, 6.3, 8.4 Hz, 1H); 31P NMR
(D2O) δ -5.87 (d, J = 22.0 Hz), -10.10 (d, J = 23.2 Hz); HRMS-EI found 413.0170 (M –
H+)-. C11H15N2O11P2 requires 413.01511; purity > 99% by HPLC (System A: 11.1 min).
5-Iodo-uridine-5′-α,β-methylenediphosphate triethylammonium salt (11)
Methylene diphosphonic acid (14 mg, 0.08 mmol) and DCC (25 mg, 0.121 mmol) were added
to a solution of 5-iodo-uridine 34 (15 mg, 0.040 mmol) in DMF (1.0 mL). The mixture was
stirred for 2 d at rt under a nitrogen atmosphere. Solvent was evaporated and the residue was
purified on Sephadex-DEAE A-25 resin and HPLC using the same method as the general
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procedure, to give the compound 11 (2 mg, 11%) as a white powder. 1H NMR (D2O) δ 8.26
(s, 1H), 5.98 (d, J = 6.1 Hz, 1H), 4.39-4.46 (m, 2H), 4.29-4.34 (m, 1H), 4.19-4.24 (m, 2H),
2.23 (t, J = 19.1 Hz, 2H); 31P NMR (D2O) δ 19.02 (d, J = 8.34 Hz), 15.04 (d, J = 8.34 Hz);
HRMS-EI found 526.9108 (M-H), C10H15IN2O11P2 requires 527.9109.
N4-Methoxycytidine-5′-diphosphate ammonium salt (12)
A solution of the N4-methoxycytidine 36 (10 mg, 0.037 mmol) and Proton Sponge (17 mg,
0.08 mmol) in trimethyl phosphate (1 mL) was stirred for 10 min at 0 °C. Then, phosphorous
oxychloride (0.008 mL, 0.08 mmol) was added dropwise, and the reaction mixture was stirred
for 2 h at 0 °C. A mixture of tributylamine (0.8 mL, 0.35 mmol) and a solution 0.35 M of the
bis(tributylammonium) salt of phosphoric acid in DMF (0.7 mL) was added at once. After 10
min 0.2 M triethylammonium bicarbonate solution (1.5 mL) was added, and the clear solution
was stirred at rt for 1 h. After removal of solvents, the residue was purified using the same
method as the general procedure using Sephadex-DEAE A-25 resin and HPLC to get
compound 12 (4.4 mg, 25%) as a white solid. 1H NMR (D2O) δ 7.23 (d, J = 8.1 Hz, 1H), 5.92
(d, J = 5.7 Hz, 1H), 5.79 (d, J = 7.8 Hz, 1H), 4.35 (m, 2H), 4.21 (m, 1H), 4.15 (m, 2H), 3.78
(s, 3H); 31P NMR (D2O) δ -7.74 (d, J = 21.4 Hz), -10.6 (d, J = 21.4 Hz); HRMS-EI found
432.0207 (M – H+)-. C10H16N3O12P2 requires 432.0209; purity > 98% by HPLC (System A:
13.6 min).
N4-Ethoxycytidine-5′-diphosphate ammonium salt (13)
A solution of the cytidine 35 (200 mg, 0.82 mmol) and O-ethylhydroxylamine hydrochloride
(160 mg, 1.64 mmol) in pyridine (2 mL) was stirred overnight at 100 °C. The reaction mixture
was concentrated, and the residue was purified on a silica gel column (CHCl3/MeOH = 10/1)
to obtain compound 37 (230 mg, 97%) as a yellow amorphous solid. 1H NMR (acetone-d6) δ
7.32 (d, J = 8.2 Hz, 1H), 5.86 (d, J = 5.1 Hz, 1H), 5.62 (d, J = 8.2 Hz, 1H), 4.27-4.21 (m, 2H),
4.07-3.95 (m, 3H), 3.79 (dd, J = 12.0, 2.8 Hz, 1H), 3.73 (dd, J = 12.0, 2.8 Hz, 1H), 1.22 (t, J
= 7.0 Hz, 3H); HRMS-EI found 288.1196 (M + H+)-. C11H18N3O6 requires 288.1185
A solution of the N4-ethoxycytidine 37 (85 mg, 0.30 mmol) and Proton Sponge (95 mg, 0.44
mmol) in trimethyl phosphate (2.5 mL) was stirred for 10 min at 0 °C. Then, phosphorous
oxychloride (0.054 mL, 0.59 mmol) was added dropwise, and the reaction mixture was stirred
for 2 h at 0 °C. A mixture of tributylamine (0.56 mL, 2.4 mmol) and a 0.35 M solution of the
bis(tributylammonium) salt of phosphoric acid in DMF (6.6 mL) was added at once. After 10
min 0.2 M triethylammonium bicarbonate solution (6.9 mL) was added, and the clear solution
was stirred at rt for 1 h. After removal of solvents, the residue was purified using the same
method as the general procedure using Sephadex-DEAE A-25 resin and HPLC to obtain
compound 13 (21.3 mg, 14%) as a white amorphous solid. 1H NMR (D2O) δ 7.24 (d, J = 8.2
Hz, 1H), 5.96 (d, J = 5.6 Hz, 1H), 5.82 (d, J = 8.2 Hz, 1H), 4.42-4.33 (m, 2H), 4.26-4.14 (m,
3H), 4.05 (dd, J = 14.1, 7.0 Hz, 2H); HRMS-EI found 446.0366 (M – H+)-. C10H16N3O12P2
requires 446.0373; purity > 98% by HPLC (System B: 7.54 min).
N4-t-Butyloxycytidine-5′-diphosphate ammonium salt (14)
A solution of the cytidine 35 (200 mg, 0.82 mmol) and O-t-butylhydroxylamine hydrochloride
(207 mg, 1.64 mmol) in pyridine (2 mL) was stirred overnight at 100 °C. The reaction mixture
was concentrated, and the residue was purified on a silica gel column (CHCl3/MeOH = 10/1)
to obtain compound 38 (143 mg, 55%) as a white solid. 1H NMR (acetone-d6) δ 7.18 (d, J =
8.2 Hz, 1H), 5.85 (d, J = 5.7 Hz, 1H), 5.56 (d, J = 8.2 Hz, 1H), 4.27-4.17 (m, 2H), 3.95 (dd,
1H, J = 6.1, 3.0 Hz), 3.80-3.68 (m, 2H), 1.26 (s, 9H); HRMS-EI found 316.1509 (M + H+)-.
C13H22N3O6 requires 316.1516.
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A solution of the N4-t-butyloxycytidine 38 (39 mg, 0.12 mmol) and Proton Sponge (40 mg,
0.19 mmol) in trimethyl phosphate (1.2 mL) was stirred for 10 min at 0 °C. Then, phosphorous
oxychloride (0.023 mL, 0.25 mmol) was added dropwise, and the reaction mixture was stirred
for 2 h at 0 °C. A mixture of tributylamine (0.24 mL, 1.0 mmol) and a 0.35 M solution of the
bis(tributylammonium) salt of phosphoric acid in DMF (2.8 mL) was added at once. After 10
min 0.2 M triethylammonium bicarbonate solution (3 mL) was added, and the clear solution
was stirred at rt for 1 h. After removal of solvents, the residue was purified using the same
method as the general procedure using Sephadex-DEAE A-25 resin and HPLC to obtain
compound 14 (12.5mg, 21%) as a white amorphous solid. 1H NMR (D2O) δ 7.12 (d, J = 8.3
Hz, 1H), 5.84 (d, J = 6.0 Hz, 1H), 5.74 (d, J = 8.3 Hz, 1H), 4.32-4.23 (m, 2H), 4.13-4.03 (m,
2H), 3.08 (dd, J = 14.7, 7.4 Hz, 12H), 1.18 (s, 9H), 1.16 (t, J = 7.3 Hz, 18H); HRMS-EI found
474.0679 (M – H+)-. C13H22N3O12P2 requires 474.0669; purity > 98% by HPLC (System B:
8.06 min).
N4-Benzyloxycytidine-5′-diphosphate ammonium salt (15)
A solution of the cytidine 35 (200 mg, 0.82 mmol) and O-benzylhydroxylamine hydrochloride
(263 mg, 1.64 mmol) in pyridine (2 mL) was stirred overnight at 100 °C. The reaction mixture
was concentrated, and the residue was purified on a silica gel column (CHCl3/MeOH = 10/1)
to obtain compound 39 (288 mg, 100%) as pale yellow amorphous. 1H NMR (acetone-d6) δ
7.40-7.26 (m, 5H), 7.23 (d, J = 8.2 Hz, 1H), 5.85 (d, J = 5.6 Hz, 1H), 5.52 (d, J = 8.2 Hz, 1H),
5.00 (s, 2H), 4.27-4.18 (m, 2H), 3.96 (dd, J = 6.1, 3.0 Hz, 1H), 3.82-3.69 (m, 2H); HRMS-EI
found 350.1352 (M + H+)-. C16H19N3O6 requires 350.1356.
A solution of the N4-benzyloxycytidine 39 (80 mg, 0.23 mmol) and Proton Sponge (74 mg,
0.34 mmol) in trimethyl phosphate (2.4 mL) was stirred for 10 min at 0 °C. Then, phosphorous
oxychloride (0.042 mL, 0.46 mmol) was added dropwise, and the reaction mixture was stirred
for 2 h at 0 °C. A mixture of tributylamine (0.43 mL, 1.83 mmol) and a 0.35 M solution of the
bis(tributylammonium) salt of phosphoric acid in DMF (5.1 mL) was added at once. After 10
min 0.2 M triethylammonium bicarbonate solution (1.5 mL) was added, and the clear solution
was stirred at rt for 1 h. After removal of solvents, the residue was purified using the same
method as the general procedure using Sephadex-DEAE A-25 resin and HPLC to obtain
compound 15 (54 mg, 47%) as a white amorphous solid. 1H NMR (D2O) δ 7.50-7.39 (m, 5H),
7.26 (d, J = 8.4 Hz, 1H), 5.95 (d, J = 5.9 Hz, 1H), 5.77 (d, J = 7.8 Hz, 1H), 5.07 (s, 2H),
4.46-4.43 (m, 1H), 4.37 (t, J = 5.7 Hz, 1H), 4.27-4.11 (m, 3H); 31P NMR (D2O) δ -7.33 (s),
-11.04 (s), -11.18(s); HRMS-EI found 508.0522 (M – H+)-. C16H20N3O12P2 requires
508.0507; purity > 98% by HPLC (System B: 9.45 min).
N4-Methoxycytidine -5′-α,β-methylenediphosphate triethylammonium salt (16)
Methylene diphosphonic acid (13 mg, 0.07 mmol) and DCC (23 mg, 0.11 mmol) were added
to a solution of N4-Methoxycytidine 36 (10 mg, 0.037 mmol) in DMF (1.0 mL). The mixture
was stirred for 2 d at rt under a nitrogen atmosphere. Solvent was evaporated and the residue
was purified on Sephadex-DEAE A-25 resin and HPLC using the same method as the general
procedure, to give the compound 16 (7.5 mg, 48%) as a white powder. 1H NMR (D2O) δ 7.30
(d, J = 8.1 Hz, 1H), 5.97 (br, 1H), 5.84 (d, J = 8.1 Hz, 1H), 4.42-4.39 (m, 2H), 4.28-4.23 (m,
1H), 4.17-4.12 (m, 2H), 3.83 (s, 3H), 2.20 (t, J = 19.5 Hz, 2H); 31P NMR (D2O) δ 18.88 (br),
14.75 (br); HRMS-EI found 430.0425 (M-H+)-, C11H18N3O11P2 requires 430.0417; purity >
98% by HPLC (System B: 6.93 min).
(S)-Methanocarba-uridine-5′-triphosphate triethylammonium salt (18)
A solution of (S)-methanocarba-uridine 41 (10 mg, 0.04 mmol) and Proton Sponge (17 mg,
0.08 mmol) in trimethyl phosphate (1 mL) was stirred for 10 min at 0 °C. Then phosphorous
oxychloride (0.008 mL, 0.08 mmol) was added dropwise, and the reaction mixture was stirred
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for 2 h at 0 °C. Tributylammonium pyrophosphate (1.6 moles C12H27N per mole H4P2O7, 110
mg, 0.23 mmol) in DMF (0.3 mL) was added at once to the reaction mixture. After 10 min,
0.2 M triethylammonium bicarbonate solution (1.5 mL) was added, and the clear solution was
stirred at rt for 1 h. After removal of solvents, the residue was purified using the same method
as the general procedure using Sephadex-DEAE A-25 resin and HPLC to get compound 18
(2.0 mg, 56%) as a white solid. 1H NMR (D2O) δ 7.78 (d, J = 7.8 Hz, 1H), 5.85 (d, J = 8.1 Hz,
1H), 4.67 (m, 1H), 4.16 (m, 3H), 2.38 (t, J = 6.3 Hz, 1H), 1.86 (m, 1H), 1.71 (t, J = 6.0 Hz,
1H), 1.30 (ddd, J = 2.1, 6.3, 8.4 Hz, 1H); 31P NMR (D2O) δ -6.76 (m), -10.7 (d, J = 20.2 Hz),
-22.63 (app t); HRMS-EI found 492.9847 (M – H+)-. C11H16N2O14P3 requires 492.9814;
purity > 98% by HPLC (System A: 17.5 min).
N4-Methoxycytidine-5′-triphosphate ammonium salt (20)
A solution of N4-methoxycytidine 36 (10 mg, 0.037 mmol) and Proton Sponge (17 mg, 0.08
mmol) in trimethyl phosphate (1 mL) was stirred for 10 min at 0 °C. Then phosphorous
oxychloride (0.008 mL, 0.08 mmol) was added dropwise, and the reaction mixture was stirred
for 2 h at 0 °C. Tributylammonium pyrophosphate (1.6 moles C12H27N per mole H4P2O7, 110
mg, 0.23 mmol) in DMF (0.3 mL) was added at once to the reaction mixture. After 10 min,
0.2 M triethylammonium bicarbonate solution (1.5 mL) was added, and the clear solution was
stirred at rt for 1 h. After removal of solvents, the residue was purified using the same method
as the general procedure using Sephadex-DEAE A-25 resin and HPLC to get compound 20
(3.9 mg, 31%) as a white solid. 1H NMR (D2O) δ 7.25 (d, J = 8.1 Hz, 1H), 5.97 (d, J = 6.3 Hz,
1H), 5.83 (d, J = 8.4 Hz, 1H), 4.40 (m, 2H), 4.22 (m, 3H), 3.81 (s, 3H); 31P NMR (D2O) δ
-8.82 (d, J = 20.2 Hz), -11.0 (d, J = 20.2 Hz), -22.40 (t, J = 19.5 Hz); HRMS-EI found 511.9873
(M – H+)-. C10H17N3O15P3 requires 511.9857; purity > 98% by HPLC (System A: 17.2 min).
P1,P3-Di(uridine-5′-)α,β-methylenetriphosphate triethylammonium salt (22)
Compound 10 (3 mg, 0.006 mmol) and UMP (1.6 mg, 0.006 mmol) were converted to the
corresponding tributylammonium salts by ion exchange. A solution of compound 10,
tributylammonium salt, and N,N′-diisopropylcarbodiimide (DIC, 2.8 μL, 0.018 mmol) in DMF
(0.06 mL) was stirred for 3 h at rt. Then a solution of the UMP tributylammonium salt in DMF
(0.04 mL) and a solution of MgCl2 (1.7 mg, 0.018 mmol) in DMF (0.02 μL) were added. After
stirring the reaction mixture at rt for 16 h, the solvent was removed and water (0.6 mL) was
added. The resulting solid was removed by filtration, and the filtrate was purified by
semipreparative HPLC as described above to obtain 22 (1.2 mg, 27 %) as a white solid.
1H NMR (D2O) δ 8.03 (d, J = 8.1 Hz, 1H), 7.98 (d, J = 8.1 Hz, 1H), 6.02-5.94 (m, 4H), 4.43-4.35
(m, 2H), 4.32-4.17 (m, 3H), 2.37 (t, J = 20.1 Hz, 1H); 31P NMR (D2O) δ 17.35 (s), 7.42 (d,
J = 27.6 Hz), -10.93 (d, J = 27.6 Hz; HRMS-EI found 751.0009 (M + 2Na+ – 3H+)-.
C19H24N4Na2O19P3 requires 751.0043; purity > 99% by HPLC (System B: 9.3 min).
P1-Uridine-5′- P3-cyclohexyl-triphosphate triethylammonium salt (25)
Compound 1 (4 mg, 0.010 mmol) was exchanged to the tributylammonium salt form. A solution
of compound 1, tributylammonium salt, and DIC (4.6 μL, 0.030 mmol) in DMF (0.08 mL) was
stirred for 3 h at rt. Then a solution of cyclohexyl phosphate tributylammonium salt in DMF
(0.08 mL) and a solution of MgCl2 (2.8 mg, 0.030 mmol) in DMF (0.04 mL) were added. After
stirring the reaction mixture at rt for 16 h, the solvent was removed and water (0.4mL) was
added. The resulting solid was removed by filtration, and the filtrate was purified by
semipreparative HPLC as described above to obtain 25 (1.35 mg, 18%) as a white solid.
1H NMR (D2O) δ 7.92 (d, J = 8.1 Hz, 1H), 7.39 (dd, J = 8.2, 8.7 Hz, 2H), 7.26 (d, J = 8.7 Hz,
2H), 7.19 (t, `J = 8.2 Hz, 1H), 5.94 (d, J = 4.5 Hz, 1H), 5.92 (d, J = 8.7 Hz, 1H), 4.38-4.32 (m,
1H), 4.30-4.18 (m, 4H); 31P NMR (D2O) δ -11.22 (d, J = 19.1 Hz), -15.71 (d, J = 19.9 Hz),
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-23.07 (t, J = 19.1 Hz); HRMS-EI found 558.9928 (M – H+)-. C15H18N2O15P3 requires
558.9920; purity > 99% by HPLC (System B: 8.9 min).
P1-Uridine-5′- P3-phenyl-triphosphate triethylammonium salt (26)
Compound 1 (4 mg, 0.010 mmol) and sodium phenyl phosphate dibasic dihydrate (5.0 mg,
0.020 mmol) were cation exchanged to the tributylammonium salts. A solution of compound
1, tributylammonium salt, and DIC (4.6 μL, 0.030 mmol) in DMF (0.08 mL) was stirred for 3
h at rt. Then a solution of phenyl phosphate tributylammonium salt in DMF (0.08 mL) and a
solution of MgCl2 (2.8 mg, 0.030 mmol) in DMF (0.04 mL) were added. After stirring the
reaction mixture at rt for 16 h, the solvent was removed and water (0.4 mL) was added. The
resulting solid was removed by filtration, and the filtrate was purified by semipreparative HPLC
as described above to obtain 26 (1.24 mg, 16%) as a white solid.
1H NMR (D2O) δ 8.02 (d, J = 8.7 Hz, 1H), 6.07-6.00 (m, 2H), 4.49-4.40 (m, 2H), 4.35-4.15
(m, 4H), 4.01-3.77 (m, 4H), 2.06-1.96 (m, 2H), 1.79-1.69 (m, 2H), 1.59-1.14 (m, 6H); 31P
NMR (D2O) δ -11.5 (br, 2H), -23.1 (br, 1H); HRMS-EI found 565.0405 (M – H+)-.
C15H24N2O15P3 requires 565.0390; purity > 99% by HPLC (System B: 9.8 min).
P1-Uridine-5′- P3-[1]glucose-1′-triphosphate triethylammonium salt (27)
Compound 1 (10 mg, 0.025 mmol) and α-D-glucose-1-phosphate disodium salt hydrate (10
mg, 0.038 mmol) were exchanged to the tributylammonium salts. A solution of compound 1,
tributylammonium salt, and DIC (12 μL, 0.075 mmol) in DMF (0.10 mL) was stirred for 3 h
at rt. Then a solution of the α-D-glucose-1-phosphate tributylammonium salt in DMF (0.10
mL) and a solution of MgCl2 (7 mg, 0.075 mmol) in DMF (0.05 μL) were added. After stirring
the reaction mixture at rt for 16 h, the solvent was removed and water (0.4 mL) was added.
The resulting solid was removed by filtration, and the filtrate was purified by semipreparative
HPLC as described above to obtain 27 (1.8 mg, 9%) as a white solid.
1H NMR (D2O) δ 7.97 (d, J = 7.8 Hz, 1H), 6.01 (d, J = 4.5 Hz, 1H), 5.99 (d, J = 7.8 Hz, 1H),
5.63 (dd, J = 7.2, 3.6 Hz, 1H), 4.45-4.37 (m, 2H), 4.32-4.22 (m, 3H), 3.97-3.73 (m, 4H), 3.52
(dt, J = 9.9, 3.3 Hz, 1H), 3.45 (t, J = 9.6 Hz); 31P NMR (D2O) δ -11.27 (d, J = 19.8 Hz), -12.65
(d, J = 19.8 Hz), -22.70 (d, J = 19.8 Hz); HRMS-EI found 645.0100 (M – H+)-.
C15H24N2O20P3 requires 645.0135; purity > 99% by HPLC (System B: 8.8 min).
(S)-Methanocarba-uridine-3′, 5′-cyclic diphosphate triethylammonium salt (9) and (S)-
Methanocarba-uridine-5′-glucose-1′-triphosphate triethylammonium salt (28)
To a solution of compound 7 (2.6 mg, 0.0036 mmol) in DMF (2 mL), 1,1′-carbonyldiimidazole
(3.0 mg, 0.018 mmol) was added. The reaction mixture was stirred at rt for 5 h. Then, 5%
triethylamine solution in 1/1 water/methanol (1 mL) was added and stirring was continued at
rt for an additional 2 h. After removal of the solvent, the residue was dried under high vacuum
and dissolved in DMF (2 mL). Glucose-1-monophosphate tributylammonium salt (4 mg, 0.006
mmol) in DMF (0.2 mL) was added to this mixture. The reaction mixture was stirred at rt for
2 d. After removal of the solvent, the residue was purified using the same method as the general
procedure using Sephadex-DEAE A-25 resin and HPLC to get compound 28 (0.8 mg, 23%)
and 9 (1.1 mg, 51%) additionally. Compound 28: 1H NMR (D2O) δ 7.79 (d, J = 8.1 Hz, 1H),
5.86 (d, J = 8.1 Hz, 1H), 5.64 (dd, J = 3.3, 7.2 Hz, 1H), 4.62 (m, 1H), 4.15 (t, J = 6.3 Hz, 2H),
3.86 (m, 4H), 3.50 (m, 3H), 2.39 (t, J = 6.3 Hz, 1H), 1.88 (dd, J = 4.8, 9.9 Hz, 1H), 1.72 (t, J
= 5.7 Hz, 1H), 1.39 (m, 1H); 31P NMR (D2O) δ -10.87 (d, J = 21.4 Hz), -12.58 (d, J = 20.76
Hz); HRMS-EI found 655.0326 (M – H+)-. C17H26N2O19P3 requires 655.0343; purity > 98%
by HPLC (System A: 16.9 min). Compound 9: 1H NMR (D2O) δ 7.81 (d, J = 8.1 Hz, 1H), 5.84
(d, J = 8.1 Hz, 1H), 5.30 (m, 1H), 4.08 (m, 3H), 2.63 (t, J = 6.3 Hz, 1H), 2.03 (m, 1H), 1.71
(t, J = 6.0 Hz, 1H), 1.50 (ddd, J = 2.1, 6.3, 8.4 Hz, 1H); 31P NMR (D2O) δ -9.55 (app d), -22.66
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(app t); HRMS-EI found 395.0044 (M – H+)-. C11H13N2O10P2 requires 395.0045; purity >
98% by HPLC (System A: 12.0 min).
5-Iodouridine-5′-glucose-1′-triphosphate triethylammonium salt (29)
Compound 3 (2 mg, 0.003 mmol) and α-D-glucose-1-phosphate disodium salt hydrate (2 mg,
0.005 mmol) were exchanged to the tributylammonium salts. A solution of compound 3,
tributylammonium salt, and DIC (1.3 μL, 0.008 mmol) in DMF (0.04 mL) was stirred for 3 h
at rt. Then a solution of the α-D-glucose-1-phosphate tributylammonium salt in DMF (0.04
mL) and a solution of MgCl2 (0.8 mg, 0.008 mmol) in DMF (0.02 μL) were added. After stirring
the reaction mixture at rt for 16 h, the solvent was removed and water (0.2 mL) was added.
The resulting solid was removed by filtration, and the filtrate was purified by semipreparative
HPLC as described above to obtain 29 (0.35 mg, 13%) as a white solid.
1H NMR (D2O) δ 8.26 (s, 1H), 6.01 (d, J = 4.8 Hz, 1H), 5.68 (dd, J = 3.0, 6.9 Hz, 1H), 4.49-4.40
(m, 2H), 4.36-4.25 (m, 3H), 4.03-3.80 (m, 4H), 3.62-3.47 (m, 2H); 31P NMR (D2O) δ -11.46
(d, J = 19.1 Hz), -12.60 (d, J = 19.1 Hz), -22.60 (t, J = 19.1 Hz); HRMS-EI found 770.9131
(M – H+)-. C15H23IN2O20P3 requires 770.9102; purity > 99% by HPLC (System B: 9.7 min).
3-Phenacyluridine-5′-glucose-1′-triphosphate triethylammonium salt (30)
Compound 5 (2 mg, 0.005 mmol) and α-D-glucose-1-phosphate disodium salt hydrate (2 mg,
0.010 mmol) were exchanged to the tributylammonium salts. A solution of compound 5,
tributylammonium salt, and DIC (2 μL, 0.015 mmol) in DMF (0.04 mL) was stirred for 3 h at
rt. Then, a solution of the α-D-glucose-1-phosphate tributylammonium salt in DMF (0.04 mL)
and a solution of MgCl2 (1 mg, 0.015 mmol) in DMF (0.02 μL) were added. After stirring the
reaction mixture at rt for 16 h, the solvent was removed and water (0.2 mL) was added. The
resulting solid was removed by filtration, and the filtrate was purified by semipreparative HPLC
as described above to obtain 30 (1.0 mg, 29%) as a white solid.
1H NMR (D2O) δ 8.08-8.04 (m, 3H), 7.80 (t, J = 7.2 Hz, 1H), 7.65 (t, J = 7.2 Hz, 2H), 6.17
(d, J = 7.8 Hz, 1H), 6.04 (d, J =4.5 Hz, 1H), 5.66 (dd, J = 3.6, 6.9 Hz), 5.55 (s, 2H), 4.49-4.43
(br, 2H), 4.37-4.29 (br, 3H), 4.01-3.77 (m, 4H), 3.60-3.50 (br, 1H), 3.48 (t, J = 9.1 Hz,
1H); 31P NMR (D2O) δ -11.24 (d, J = 25.4 Hz), -12.63 (d, J = 25.4 Hz), -22.65 (d, J = 25.8
Hz); HRMS-EI found 763.0554 (M – H+)-. C23H30N2O21P3 requires 763.0589; purity > 99%
by HPLC (System B: 9.9 min).
Uridine-5′-glucose-1′-α,β-methylenetriphosphate triethylammonium salt (31)
Compound 10 (2.4 mg, 0.004 mmol) and α-D-glucose-1-phosphate disodium salt hydrate (3.6
mg, 0.012 mmol) were exchanged to the tributylammonium salts. A solution of compound
10, tributylammonium salt, and DIC (1.8 μL, 0.012mmol) in DMF (0.04 mL) was stirred for
3 h at rt. Then, a solution of the α-D-glucose-1-phosphate tributylammonium salt in DMF (0.04
mL) and a solution of MgCl2 (2.6 mg, 0.028 mmol) in DMF (0.02 μL) were added. After stirring
the reaction mixture at rt for 16 h, the solvent was removed and water (0.4 mL) was added.
The resulting solid was removed by filtration, and the filtrate was purified by semipreparative
HPLC as described above to obtain 31 (2.7 mg, 80%) as a white solid.
1H NMR (D2O) δ 8.07 (d, J = 7.8 Hz, 1H), 6.06-5.99 (m, 2H), 5.70-5.63 (m, 1H), 4.49-4.43
(m, 2H), 4.35-4.27 (m, 1H), 4.27-4.21 (m, 2H), 4.00-3.77 (m, 4H), 3.60-3.43 (m, 2H), 2.43 (t,
J = 19.8 Hz, 2H); 31P NMR (D2O) δ 17.32 (d, J = 9.1 Hz), 8.27 (dd, J = 9.1, 26.7 Hz), -12.23
(d, J = 26.7 Hz); HRMS-EI found 643.0348 (M – H+)-. C16H26N2O19P3 requires 643.0343;
purity > 99% by HPLC (System B: 9.2 min).
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N4-Methoxycytidine-5′-glucose-1′-triphosphate triethylammonium salt (32)
Compound 12 (4.9 mg, 0.009 mmol) and α-D-glucose-1-phosphate disodium salt hydrate (8.4
mg, 0.028 mmol) were exchanged to the tributylammonium salts. A solution of compound
12, tributylammonium salt, and DIC (4.3 μL, 0.028 mmol) in DMF (0.1 mL) was stirred for 3
h at rt. Then, a solution of the α-D-glucose-1-phosphate tributylammonium salt in DMF (0.1
mL) and a solution of MgCl2 (2.6 mg, 0.028 mmol) in DMF (50 μL) were added. After stirring
the reaction mixture at rt for 16 h, the solvent was removed and water (1 mL) was added. The
resulting solid was removed by filtration, and the filtrate was purified by semipreparative HPLC
as described above to obtain 32 (0.62 mg, 10%) as a white solid.
1H NMR (D2O) δ 7.28 (d, J = 8.4 Hz, 1H), 5.99 (d, J = 5.4 Hz, 1H), 5.86 (d, J = 8.4 Hz, 1H),
5.65 (dd, J = 3.6, 7.2 Hz, 1H), 4.45-4.36 (m, 2H), 4.30-4.15 (m, 3H), 3.97-3.77 (m, 4H), 3.82
(s, 3H), 3.57-3.50 (m, 1H), 3.47 (t, J = 9.3 Hz, 1H); 31P NMR (D2O) δ -11.27 (d, J = 19.1 Hz),
-12.65 (d, J = 19.1 Hz), -22.71 (t, J = 19.1 Hz); HRMS-EI found 674.0387 (M – H+)-.
C16H27N3 O20P3 requires 674.0401; purity > 99% by HPLC (System B: 9.3 min).
N4-Methoxycytidine-5′-phenyl-triphosphate triethylammonium salt (33)
Compound 12 (6.9 mg, 0.011 mmol) and sodium phenyl phosphate dibasic dihydrate (8.3 mg,
0.033 mmol) were exchanged to the tributylammonium salts. A solution of compound 12
tributylammonium salt and DIC (5.0 μL, 0.033 mmol) in DMF (0.07 mL) was stirred for 3 h
at rt. Then, a solution of the phenyl phosphate tributylammonium salt in DMF (0.07 mL) and
a solution of MgCl2 (3.1 mg, 0.033 mmol) in DMF (0.07 mL) were added. After stirring the
reaction mixture at rt for 16 h, the solvent was removed and water (1 mL) was added. The
resulting solid was removed by filtration, and the filtrate was purified by semipreparative HPLC
as described above to obtain 33 (0.9 mg, 14%) as a white amorphous solid.
1H NMR (D2O) δ 7.44-7.36 (m, 2H), 7.31-7.17 (m, 4H), 5.92 (d, J = 6.0 Hz, 1H), 5.77 (d, J =
8.4 Hz, 1H), 4.38-4.28 (m, 2H), 4.24-4.15 (m, 3H); HRMS-EI found 588.0186 (M – H+)-.
C16H22N3 O15P3 requires 588.0199; purity > 99% by HPLC (System B: 10.3 min).
Pharmacological analyses
UDP was purchased from Sigma (St. Louis, MO). Myo-[3H]inositol (20 Ci/mmol) was obtained
from American Radiolabeled Chemicals (St. Louis, MO). Measurement of intracellular
calcium ion concentration in response to nucleotides was performed as described.4
Assay of PLC activity stimulated by P2Y2, P2Y4, and P2Y6 receptors
Stable cell lines expressing the human P2Y2, P2Y4, or P2Y6 receptor in 1321N1 human
astrocytoma cells were generated as described.26 Agonist-induced [3H]inositol phosphate
production was measured in 1321N1 cells plated to 20,000 cells/well on 96-well plates two d
prior to assay. Sixteen h before the assay, the inositol lipid pool of the cells was radiolabeled
by incubation in 100 μL of serum-free inositol-free Dulbecco's modified Eagle's medium,
containing 1.0 μCi of myo-[3H]inositol. No changes of medium were made subsequent to the
addition of [3H]inositol. On the day of the assay, the cells were challenged with 25 μL of a
fivefold concentrated solution of receptor agonists in 200 mM HEPES (N-(2-hydroxyethyl)-
piperazine-N′-2-ethanesulfonic acid), pH 7.3 in HBSS, containing 50 mM LiCl for 30 min at
37°C. Incubations were terminated by aspiration of the drug-containing medium and addition
of 450 μL of ice-cold 50 mM formic acid. [3H]Inositol phosphate accumulation was quantified
using scintillation proximity assay methodology as previously described in detail.26
Maruoka et al. Page 14














Agonist potencies (EC50 values) were determined from concentration-response curves by non-
linear regression analysis using the GraphPad software package Prism (GraphPad, San Diego,
CA). All experiments examining the activity of newly synthesized molecules also included full
concentration effect curves for the cognate agonist of the target receptor: UTP for the P2Y2
receptor, UTP for the P2Y4 receptor, and UDP for the P2Y6 receptor. Each concentration of
drug was tested in triplicate assays, and concentration effect curves for each test drug were
repeated in at least three separate experiments with freshly diluted molecule. The results are
presented as mean ± SEM from multiple experiments or in the case of concentration effect
curves from a single experiment carried out with triplicate assays that were representative of
results from multiple experiments.
Stability of Nucleotide Derivatives
UTP was purchased from Sigma (St. Louis, MO). Up3U 19 was synthesized by the procedure
previously reported.21 HCl buffer (pH 1.2) solution was prepared as follows. Concentrated
HCl (7 mL, 12 N) was added to 2.0 g of sodium chloride and diluted with water to a volume
of 1000 mL. Membranes were prepared as follows. P2Y1 receptor-expressing astrocytoma
cells were grown to 80% confluence and then harvested. The cells were homogenized and the
nuclear fraction was removed by centrifuging at 100 × g for 5 min. The pellet was resuspended
in 50 mM tris(hydroxymethyl)aminomethane (Tris) hydrochloride buffer (pH 7.4). The
suspension was homogenized with a polytron homogenizer (Brinkmann) for 10 s and was
ultracentrifuged at 20,000 × g for 20 min at 4°C. The resultant pellets were resuspended in Tris
buffer (pH 7.4), and the membrane was stored at -80° C until the experiments. The protein
concentration of the membrane preparation was measured by Bradford assay.34 The membrane
preparation was diluted with 4 mL of Dulbecco's Phosphate-Buffered Saline (pH 7.4) and
homogenized before use for the stability check. The final protein concentration was 14.9 μg/
mL.
Ten μL of a 2 mg/mL aqueous solution of each nucleotide derivative was mixed with 90 μL
of HCl buffer (pH 1.2) or the membrane suspension and incubated at 37°C. At regular intervals,
a 6 μL aliquot of the above mixture was mixed with 54 μL of water or 5 mM TBAP. Then, 50
μL of the mixure was injected to the HPLC.
AUC of compounds were measured using a Hewlett–Packard 1100 HPLC equipped with a
Zorbax Eclipse 5 μm XDB-C18 analytical column (250 × 4.6 mm; Agilent Technologies Inc,
Palo Alto, CA). Mobile phase: linear gradient solvent system: 5 mM TBAP-CH3CN from 80:20
to 40:60 in 6.5 min; the flow rate was 1 mL/min (System C) or System B. Peaks were detected
by UV absorption with a diode array detector at 254, 275, and 280 nm and AUC were calculated
based on the peak at 254 nm.
Molecular Modeling
P2Y6 - Compound 7 complex—Molecular modeling was based on our previously
published model of the complex between UDP and the rhodopsin-based P2Y6 receptor,
obtained through MonteCarlo conformational searches and molecular dynamics in a hydrated
lipid bilayer.13
Here, compound 7 was sketched from the docked UDP, and subsequently subjected to a series
of energy minimizations allowing flexibility to increasingly larger portions of the model,
followed by a conformational search. In particular, the minimizations were performed on the
cyclopropane moiety of the ligand, the ribose moiety of the ligand, and the entire ligand. The
final minimization and the conformational search were performed on the entire ligand plus all
the P2Y6 residues and the water molecules located within a radius of 5 Å. All of the atoms
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within an additional shell of a radius of 3 Å were also taken into account in the calculations as
a frozen environment.
All the calculations were conducted using MacroModel, version 9.6, as implemented in the
Schrödinger package, with the OPLS_2005 force field and water as implicit solvent (GB/SA
model).35 The minimizations were based on the Polak-Ribier conjugate gradient algorithm and
were performed with a threshold on the gradient of 0.05 KJ/Mol. The conformational search
was based on 1000 steps of extended Monte Carlo Multiple Minimum (MCMM) torsional
sampling. The sampling regarded the torsional angles of residues and ligand, as well as the
rotation and translation of the ligand.
P2Y6 - Compound 12, 26 or 33 complex—Molecular modeling was based on the same
structure described in the above section. Compounds 12, 26 and 33 were sketched from the
docked UDP, and subsequently subjected to a series of energy minimizations allowing
flexibility to increasingly larger portions of the model, followed by a conformational search.
All the conformational searches were performed on each entire ligand plus all the P2Y6 residues
located within a radius of 6 Å from the initial ligand, UDP. All of the atoms within an additional
shell of a radius of 4 Å were also taken into account in the calculations as a frozen environment.
All the calculations were conducted using MacroModel, version 9.7.1, as implemented in the
Schrödinger package, with the OPLS_2001 force field.36 The minimizations were based on
the Polak-Ribier conjugate gradient algorithm and were performed with a threshold on the
gradient of 0.05 KJ/Mol. The conformational search was based on 100 steps of extended Monte
Carlo Multiple Minimum (MCMM) torsional sampling. The sampling regarded the torsional
angles of residues and ligand, as well as the rotation and translation of the ligand.
Residue indexing—To facilitate the comparison among receptors, residues are identified
through the GPCR residue indexing system. In each TM, the index X.50, where X is the TM
number, is assigned to the position hosting the most conserved residue among class A GPCRs.
All other positions in the TM are numbered relatively to the X.50 position.37
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Structures of prototypical agonist ligands for studying P2Y6 receptors.
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Synthesis of various pyrimidine ribonucleoside 5′-di and triphosphate derivatives. Reagents
and conditions: (a) DCC, methylenebisphosphonate, rt, overnight, 11 % for 11, 48 % for 16;
(b) RONH2, pyridine, 90°C, overnight, 55 – 100 %; (c) POCl3, Proton Sponge, PO(OMe)3, 0°
C, 2 hr, followed by tributylammonium phosphate, rt, 0.5 hr (for 12 - 15), 14 – 47 %; (d)
POCl3, Proton Sponge, PO(OMe)3, 0°C, 2hr, followed by tributylammonium pyrophosphate,
rt, 0.5 hr, 31 % (for 20).
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Synthesis of various pyrimidine ribonucleoside 5′-triphosphates and dinucleoside
triphosphates. Reagents and conditions: (a) DIC, MgCl2, glucose 1-monophosphate
tributylammonium salt, DMF, rt, overnight, 9 - 80 %; (b) DIC, MgCl2, respective
monophosphate tributylammonium salt, e.g., uridine 5′-monophosphate, 35, cyclohexyl
monophosphate16 or phenyl monophosphate, in DMF, rt, overnight, 9–80%. Unless noted, X
= H and Y, Z = O.
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Synthesis of uracil ribonucleoside phosphate derivatives constrained with a (S)-methanocarba
ring. Reagents and conditions: (a) POCl3, Proton Sponge, PO(OMe)3, 0°C, 2 hr; then
tributylammonium phosphate, rt, 0.5 hr, 45 %; (b) POCl3, Proton Sponge, PO(OMe)3, 0°C, 2
hr; then tributylammonium pyrophosphate, rt, 0.5 hr, 56 %; (c) CDI, DMF, rt, 1 hr, then glucose
1-monophosphate tributylammonium salt, overnight, 23 % for 28, 51 % for 9.
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A) Activity of agonists 7, 12, 15, and 23 at the human P2Y6 receptor as indicated by activation
of PLC in stably transfected 1321N1 human astrocytoma cells. The effect of UDP corresponds
to 100%. B) Mobilization of intracellular calcium in astrocytoma cells expressing the human
P2Y6 receptor (EC50 values shown in nM) by nucleotide agonists 3 (50), 21 (370), 23 (83),
and 24 (630). The EC50 value of 1 was 200 nM.
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Molecular modeling of the human P2Y6 receptor. A) Details of the nucleotide binding site of
the receptor complexed with the agonist 7 as obtained after a fully flexible Monte Carlo
conformational search. The ligand is represented as balls and sticks, colored by element. The
binding pocket is represented as a van der Waals surface colored according to the electrostatic
potential, with positive charges in blue and negative charges in red. For clarity, the residues
located in front of the ligand are represented as sticks, colored by element. Labels indicate all
of the residues represented as sticks (adjacent) and the key residues represented as van der
Waals surfaces (trough arrows). A schematic representation of the receptor-ligand complex is
given in the lower left inset. In the tube representations the receptor is colored according to
residue positions, with a spectrum of colors that ranges from red (N-terminus) to purple (C-
terminus): TM1 is in orange, TM2 in ochre, TM3 in yellow, TM4 in green, TM5 in cyan, TM6
in blue, TM7 in purple. B) Docking of the potent agonist N4-methoxy-cytidine-5′-diphosphate
12. A hydrophobic binding pocket for the N4-alkyloxy substituent is defined in this docking
model. Distances in Å from the methoxy carbon atom to neighboring amino acid residues are
shown.
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Table 1
Potencies of (S)-methanocarba analogues 6, 7, and 9, in relation to known uridine 5′-diphosphate derivatives for
activation of the human P2Y6 receptor. Unless noted: R = uridine; and X = O.
Compound Modification Structure EC50, μMa
hP2Y6
1 UDP - 0.30±0.06
2 dUDP R = H 1.72±0.76
3b 5-I-UDP X = 5-I 0.015±0.002
5b phenacylUDP X = 3-Ph-COCH2 0.070±0.006
6b (S)-methanocarba dUDP R = H 0.23±0.05
7 (S)-methanocarba UDP - 0.042±0.008
8b,d (N)-methanocarba UDP NE
9 (S)-methanocarba U-cyclic 3′,5′-diphosphate NE
10b α,β-CH2-UDP Y = CH2 0.70±0.11
11 α,β-CH2-5-I-UDP X = 5-I, Y = CH2 0.13±0.02
c6, MRS2633; 7, MRS2795.
eEC50 values33 (μM) reported in activation of the hP2Y14 receptor expressed in HEK-293 cells: 1, 0.16±0.04; 10, 0.011±0.005; 11, 0.014±0.07.
NE – no effect at 10 μM.
a
Agonist potencies reflect stimulation of phospholipase C in 1321N1 human astrocytoma cells stably expressing the human P2Y6 receptor. Potencies
are presented in the form of EC50values, which represent the concentration of agonist at which 50% of the maximal effect is achieved. These values
were determined using a four-parameter logistic equation and the GraphPad software package (GraphPad, San Diego, CA). The results are presented
as mean ± standard error and are the average of three to six different experiments with each molecule.
b
Values reported in literature: 3, Besada et al.14; 5, El-Tayeb et al.8; 6 and 8, Costanzi et al.13; 10, Ko et al.16
d
Structure of 8 given in Chart 1.
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Table 4
Half-lives of nucleotide (5′-triphosphate) derivatives when incubated at 37°C in acidic aqueous solution or in the
presence of mammalian (1321N1 human astrocytoma) cell membranes, determined by HPLC.
Compound t1/2, h (pH 1.2) t1/2, h (membranes) Pharmacological properties at hP2Y6 receptor
12, N4-MeO-CDP 116 55 selective, potent agonist
15, N4-BnO-CDP 126 26 selective, potent agonist
17, UTP 23 31 ~inactive
21, Up3U 218 42 moderately potent agonist, only 4-5 fold selective
22, α,β-me-Up3U 34 62 weak agonist, selective
23, N4-MeO-Cp3U 120 23 selective, potent agonist
25, Up3-O-cyclohexyl 193 62 weak agonist, nonselective vs. P2Y2 receptor
26, Up3-O-Ph 164 43 weak agonist, selective
27, Up3-gluc 5.1 29 ~inactive
31, α,β-me-Up3-gluc 2.8 19 ~inactive
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